Episode 101: With Charcot Award Recipient Professor Catherine Lubetzki

Welcome back to Part Two of our coverage of the 2026 ACTRIMS Forum. This week, we shift our focus to emerging therapies and clinical insights that are re-shaping the future of MS care. From the latest...

16 Helmi 44min

Last week, over 1,400 scientists and clinicians gathered in San Diego, California, at the 2026 Americas Committee for Treatment and Research in Multiple Sclerosis annual meeting, better known as the A...

9 Helmi 33min

This past December, the FDA issued a Complete Response Letter to drug manufacturer Sanofi in response to Sanofi's application seeking approval for Tolebrutinib, the first in a new category of investig...

2 Helmi 39min

The first coordinated global research strategy to prevent MS has been announced. This week, Dr. Bruce Bebo, the National MS Society's Executive Vice President and Chief Research & Medical Affairs Offi...

26 Tammi 32min

One of the more confusing aspects of MS is that it can present differently from one person to the next. A research team at University College London may have uncovered a reason for that when they iden...

19 Tammi 29min

I don't have to remind anyone who listens to this podcast that the cost of MS disease-modifying therapies is obscenely high. And we're not just talking about relatively new medications. Older medicati...

12 Tammi 29min

Scientists are expanding our understanding of MS at an unprecedented pace. This week, Dr. Leorah Freeman discusses why, as new discoveries and medications enter clinical practice, neurologists and MS ...

5 Tammi 34min

We're closing out the year by revisiting the most listened-to episode of RealTalk MS in 2025. And it shouldn't come as a major surprise that this year's most listened-to episode was our review of the ...

29 Joulu 202524min